Philips and Prisma Health Sign Multi-year, Long-term Strategic Partnership

Philips and Prisma Health, South Carolina’s largest non-profit healthcare system, today announced they have entered into a multi-year agreement to help the health system achieve enterprise interoperability, standardize patient monitoring, and drive innovation in enterprise imaging solutions to enhance patient care and improve clinical performance.

As South Carolina’s largest private, non-profit healthcare system, and second-largest private company, Prisma Health wants to deliver on the quadruple aim: improve patient and staff satisfaction, lower costs, and improve outcomes for all South Carolinians.

Prisma Health was formed in 2017 when Greenville Health System and Palmetto Health, two of South Carolina’s most highly regarded healthcare systems, came together as one organization. Today, Prisma Health has nearly 3,000 licensed beds and 18 acute care and specialty hospitals, as well as 270 physician practices servicing 21 counties. They treat over one million unique patients across their networks each year, including 368,000 virtual care visits, and just under half a million emergency department visits.

“When our two regional healthcare organizations merged, an enterprise-wide technology strategy became critical to standardize best practices across the whole system, creating new bridges between hospital and home care and continuing to drive innovation,” said Rich Rogers, Senior Vice President, Chief Information Officer, Prisma Health. “At Prisma Health, we wanted to engage a partner to help us address data integration and unlock the power of patient data so that we are able to provide our patients with the best care anywhere in our service areas. We want to put the right tools into the hands of our clinicians to allow them to better share information, collaborate and help transform care for the communities we serve.”

With the Philips HealthSuite secure cloud platform at its foundation, Philips is committed to enterprise interoperability. Philips’ solutions portfolio includes real-time patient monitoring, therapeutic devices, telehealth, image management and informatics solutions including radiology and cardiology PACS, advanced visualization, vendor neutral archive (VNA) and Philips Enterprise Viewer – Vue Motion, and interoperability solutions, including the industry-leading Philips Capsule Medical Device Information Platform.

Prisma Health will not only have access to these technologies, they will also be the largest installation of the Philips Enterprise Performance Analytics – Performance Bridge – analytics platform in North America. Performance Bridge gives healthcare professionals access to near real-time data on departmental performance through an easy-to-use interactive dashboard. Vendor agnostic, Performance Bridge unifies information across different imaging modalities and informatics solutions to optimize organizational efficiency, drive adherence to standards of care and facilitates additional revenue streams. Prisma Health plans to use Performance Bridge to drive innovation and monitor their delivery of quality healthcare.

“At Philips, we made a deliberate decision to create an end-to-end enterprise strategy that will help our customers overcome interoperability barriers and enable data sharing,” said Vitor Rocha, Chief Market Leader for Philips North America. “Health systems shouldn’t have to worry about integrating technology, which is why we have developed vendor-agnostic solutions based on standards and frameworks that bring together data from applications, systems, and devices. This allows our partners to focus on what is most important to them and their patients – continuously improving the patient journey and outcomes.”

Long-term strategic partnerships (LSPs) are a growing trend within hospitals and health systems to better manage the cost and complexity of their technology investments over a defined period of time, while expanding quality access to advanced medical care to improve patient outcomes. Philips is a leader in LSPs and continues to work with forward-thinking organizations like Prisma Health to develop standards, best practices, and predictive technologies that can redefine the future of healthcare.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”